| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 23016 |
| Drug | Ivosidenib |
| Brand | Tibsovo® |
| Indication | For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R 132 mutation who were previously treated by at least one prior line of systemic therapy |
| Assessment Process | |
| Rapid review commissioned | 08/03/2023 |
| Rapid review completed | 17/04/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ivosidenib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/06/2023 |
| Pre-submission consultation with Applicant | 05/09/2023 |
